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Summary.-Twenty-four untreated patients with myelomatosis were studied in
order to characterize their anaemia, using standard haematological and ferrokinetic
techniques, together with measurements ofcirculating erythropoietin, erythropoietin
sensitivity of marrow cultures and in vitro measurements of haem synthesis.
There is a reduction in total erythroid output by the marrow, together with a
minor degree ofplasma expansion. In patients with normal renal function there is an
appropriate increase in erythropoietin in response to anaemia, but in a few cases there
may be reduced response of CFU-E to the hormone in vitro. No abnormality of iron
status or haem synthesis was found. One case of folate deficiency was discovered.
ANAEMIA IS COMMON in patients with
myelomatosis. Nearly half the patients
entering the third MRC myelomatosis
trial had an initial haemoglobin concen-
tration of 10 g/dl or less (MRC Working
Party, 1980a). The haemoglobin concen-
tration on presentation was strongly
correlated with prognosis in patients with
good renal function (ibid.) though in
patients with poor renal function it
appeared to give little prognostic informa-
tion. The pathogenesis of anaemia in
patients with myelomatosis and the rea-
sons for its prognostic significance are
unknown. The purpose of the present
study is to characterize the anaemia
found in newly diagnosed, untreated
patients, using standard haematological
and ferrokinetic techniques. These results
have been related to measurements of
erythropoietin, the erythropoietin sensi-
tivity of marrow cultures and haem
synthesis in erythroblasts.
PATIENTS AND METHODS
Patients.-Twenty-four newly diagnosed,
untreated patients with myelomatosis gave
their fully informed consent to the investi-
gations carried out in this study. There
were 12 male and 12 female patients, aged
43-89 years (mean 65). The diagnosis of
myelomatosis was based on at least 2 of
the following 3 criteria: (1) marrow smears
showing the presence of abnormal plasma-
cell infiltration, (2) radiological evidence of
definite osteolytic lesions, (3) paraprotein
or Bence Jones protein in the serum or urine.
Patients presenting with renal failure were
adequately hydrated before any investi-
gations were carried out.
The patients were clasisfied by their haemo-
globin concentration, serum calcium, serum
and urine paraprotein and light-chain con-
centrations, and radiological lesions at pre-
sentation into 3 clinical stages, according to
the method of Durie & Salmon (1975). There
were 10 patients with IgG myeloma, 7 with
IgA myeloma, I with IgM myeloma, 4 with
K light-chain myeloma and 2 with A light-
chain myeloma. Thirteen patients had Bence
Jones proteinuria. Haematological and ferro-
kinetic data were also available from 11
male and 9 female normal healthy adult
volunteers aged 27-64 years (mean 40).
Marrow cultures were carried out on samples
from 7 male and 7 female normal adults,
aged 20-64 years (mean 51).
Methods.-Haemoglobin concentration and
red-cell indices were measured with a Coulter
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Counter model S. Serum iron concentration
and total iron-binding capacity were meas-
ured by a modification of the method of
Young & Hicks (1965). Serum ferritin con-
centration was measured by the immuno-
radiometric assay described by Jones &
Worwood (1975). The method of Tennant
(1977) was used to measure the serum and
red-cell folate concentrations. The serum
paraprotein type was determined by immuno-
electrophoresis. The concentration of normal
immunoglobulins was measured by radial
agar immunodiffusion (Fahey & McKelvey,
1965) using commercially available standards.
Serum erythropoietin concentration was
assayed using foetal mouse liver cell
cultures by the technique of Napier & Evans
(1980).
Ferrokinetic measurements were made of
erythroid and non-erythroid iron turnover
and mean red-cell lifespan, together with
plasma volume and total red-cell volume
by the methods described by Ricketts et al.
(1975) and Cavill et al. (1977). Total marrow
erythroblast population and the mean in
vivo erythroblast iron uptake were estimated
from measurements of the radioactivity in
marrow cells aspirated 20-24 h after i.v.
injection of [59Fe] transferrin (Cavill &
Fisher, in preparation). The total radio-
activity in the marrow at this time wvas
derived by analysis of the plasma iron clear-
ance and red-cell utilization curves. The
total number of erythroblasts in the marrow
was calculated from this value and the meas-
ured activity of the known number of
nucleated red cells in the marrow sample.
The total marrow plasma-cell population
was calculated from the total marrow erythro-
blast count, assuming that the plasma cell/
erythroblast ratio in the marrow aspirate
was representative of the total marrow.
Erythroblast iron metabolism was also
studied in vitro in aspirated marrow samples.
Washed marrow cells were incubated for
1 h in Hepes buffered MEM (pH 7.4) con-
taining 2 mg/ml transferrin. 38% saturated
with [59Fe] ferric iron. At the end of this
time total iron uptake in erythroblasts was
measured. The washed cells were then soni-
cated and 59Fe was measured in the cell
stroma after centrifugation at 45,000 g for
30 min. 59Fe in haem was measured after
butanone extraction of the supernatant
cytosol, and 59Fe incorporation into ferritin
was measuired after precipitation by rabbit
antihuman-spleen ferritin following the addi-
tion of carrier ferritin. The remaining cytosol
59Fe in unidentified soluble complexes was
also measured.
The erythropoietin (Epo) response of
marrow cells was measured in liquid culture
by a modification of the method described
by Krantz et al. (1963, 1973). Briefly, 2 x 106
marrow cells in 64% of medium (Flow Labs)
and 300% pooled, heat-inactivated, human
AB serum were cultured in duplicates with
and without Epo (Connaught Laboratorie.
anaemic sheep Step III Epo, Lots 3034-1
and 3026-1). After incubation of 72 h the
cells were labelled with 0 5 HCi of [59Fe
transferrin, and after a further 18 h incuba-
tion, haem was extracted from the washed
cells by a modification of the method of
Teale (1959). The incorporation of 59Fe
into haem was then counted in an LKB
80,000 automatic gamma counter. None of
the parameters measured showed a Normal
distribution. Correlations wNere assessed using
Spearman's rank correlation coefficient and
difference between groups by the Mann-
Whitmey U test (Siegel, 1956).
RESULTS
Clinical stages and total marrow plasma-cell
counts
Total plasma-cell population was esti-
mated in only 12 patients. Three in Stage
1 (Durie and Salmon, 1975) had between
0410 and 3 34 x 1.011; 2 in Stage II had
0 54 and 12 58 x 1011; and 7 in Stage
III had between 1P81 and 5-73 x 1011.
The percentage of plasma cells in the
marrow ranged from 10% to 700o and
did not appear to be related to the clinical
staging.
Renalfunction
Six patients had a blood-urea con-
centration of > 10 mm and 5 had a serum
creatinine of > 200 jM. There was a
significant negative correlation between
haemoglobin concentration and serum
creatinine (rs= - 052, P < 0.05) but no
correlation between the concentrations
of haemoglobin and blood urea (rs=
-0*31, P<0-1). Neither haemoglobin
concentration, marrow iron turnover,
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TABLE I. Haemnatological and biochemical variables in 24 patients with myelomatosis
Haemoglobin concentration (g/dl)
Mean corpuscular volume (fl)
Mean corpuscular haemoglobin (pg)
Blood urea (mM)
Serum creatinine (tLM)
Serum iron (/im)
Total iron binding capacity (MM)
Transferrin saturation (%)
Serum ferritin (pg/l)
Serum folate (,ug/1)
Red cell folate (*g/l)
Serum paraprotein (g/l)
IgG (10)*
IgA (7)
IgM (1)
Serum immunoglobulins (g/l)
IgG (14)
IgA (18)
IgM (23)
* No. of patients in brackets.
haem synthesis nor the in vitro response
of the marrow to Epo were significantly
different between patients with blood
urea concentrations above and below
10 mM.
Immunoglobulins
The serum paraprotein levels of the
patients are summarized in Table 1.
Thirteen patients had immunoparesis and
their immunoglobulins were below the
normal laboratory reference value shown
in Table I. The serum paraprotein level
was significantly correlated with the
percentage of plasma cells in the marrow
(rs=0*70, P < 001) with the total marrow
plasma cells (rs=0.76, P<0-01), total
blood volume (rs = 0-63, P < 0.05) and
with serum folate concentration (rs=
-0 73, P<0-001). In the patients with
light-chain myeloma, urinary concentra-
tion oflight chains varied between 0 4 and
12*1 g/l (mean 5.0 g/l).
Haematological status
The haematological and biochemical
statuses of the patients are summarized
in Table I. Nine of the patients had a
haemoglobin concentration of < 10 g/dl.
Normal
reference
values
11 9-17-1
86-104
27 0-32-0
2 5-7 5
60-120
12-34
45-70
25-50
14-370
2 1-21
120-600
38 8
31 0
8 3
4-5-16-0
1-2-4-0
0-45-1-8
Myelomatosis
patients
Mean Range
10-7 7-1-15-3
93 81-116
30-6 26-5-37-6
11-3 3:4-58-5
202 70-1260
12-4 15-33-0
51-8 205-95-0
24-0 7-3-53-2
197 27-745
5 8 1-9-13-1
313 60-752
16-7-59-1
777-57 0
3 3-58 5
< 0 6-9-0
< 0 2-2 0
There was a significant negative correla-
tion between haemoglobin concentration
and serum paraprotein (rs = -056, P <
0.05), total marrow plasma cells (r,=
-0-62, P<0 05) and total blood volume
(rs= -0-71, P<0-01). Haemoglobin con-
centration was significantly correlated
with the percentage of plasma cells in
the marrow (rs= -0'43, P < 0.05).
Stainable iron was present in the
marrow of all the patients, but no sidero-
blasts or megaloblasts were seen. Four
patients had both low serum iron and
total iron binding capacity, but a low
transferrin saturation was found only
in 3 patients. No patient had a serum
ferritin < 15 jug/l, the level conventionally
denoting iron deficiency. One patient
had a low serum folate (1-9 ,ug/l) and
red-cell folate of 60 [kg/l.
Serum erythropoietin
The serum Epo concentrations of the
uraemic patients were all within the
normal range of 3-30 mu/ml (Fig. 1).
Four anaemic patients without renal
failure had raised serum Epo con-
centrations appropriate to the degree of
anaemia.
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2001 C' Blood volume andferrokinetic studies
The comparison of blood volume and
ferrokinetic measurements in normal sub-
1i0- jects and patients is summarized in
0 Table II. The mean blood volume was
^s - 8 significantly higher in myeloma patients
s50- s (68.6 ml/kg) than in normal subjects
(63.0 ml/kg) though the degree of haemo-
dilution implied by this relatively small
difference would not be sufficient by itself
to account for the difference in haemo-
globin concentration between the groups.
Lbi 100 Total marrow iron turnover is significantly
lower in myeloma patients (81 jtmol/l/d)
g / / / / / X than in normal subjects (115 pmol/l/d)
but there was no difference in the degree
of ineffective iron turnover. The mean
3- NO////////////////////////////// marrow iron turnover in Stage I patients
was 101U5 ,umol/l/d, in Stage II patients
82-0 pmol/l/d and in Stage III patients
58 0 pmol/l/d. These differences are not
however, statistically significant, possibly
because of the small numbers involved.
B100d Lrea Blbod Urea1 The mean red-cell lifespan was similar
<10mM x0mm in the two groups and there was no
FIo. 1. The relationslip I)etween serum difference in non-erythroid iron turnover.
erythropoietin and blood urea in anaemic The total erythroblast population was
(0) and( non-anaemic (a) patients with measured only in 5 of the normalsubjects, myelomatosis. Shaded area represents
normal range. and a range of 2 06-5-67 x 109 cells/kg
TABLE II.-Blood volume and ferrokinetic measurements in 20 normal subjects and 16
patients with myelomatosis (mean and range)
Plasma volume (ml/kg)
Red-cell volume (ml/kg)
Blood volume (ml/kg)
Marrow ironi turnover (MIT)
(4tM/day)
Ineffective ironl turnover (% of MIT)
AMean red-cell lifespail (days)
Non-erytlhroidl iron turnover
( uM/day)
Total erythroblast count ( x 1(6/kg)
Erythroblast iron uptake
(,M/1012 cells/day)
Normal
39 6
31* 9-50* 7
25 1
20 4-33 ()
63-0
52 3-74 7
1115
73-145
23
13-34
96
67-153
29
5-57
4-1
2> *1-5 * 7
2198
1503-3167
Myeloma
49-8
38-3-62-9
18 8
13 2-23 '9
68 6
535-82 3 3
81
33-135
21
8 -39
98
57-166
23
1-52
3 3
l 0-9*4
1939
884-4452
U P
42 < 0*002
17 <0 002
83 <0 05
65 < 0 *002
126 n.s.
157 n.s.
134 n.s.
20 n1.S.
18 uI.S.
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cell lifespan. There is no difference in
erythroblast iron uptake in vivo between
normal and myeloma subjects.
In vitro erythroblast iron metabolism
The erythroblast iron uptake in normal
subjects ranged from 7 to 30 tumol/102
cells/h(mean15,mol)andthiswasincreased
in 8 ofthe 17 patients studied. The cytosol
iron incorporated into haem in the normal
subjects was 55-84%. In 3 patients with
high erythroblast iron uptake the per-
centage incorporation into haem was
somewhat less, but the absolute amount
incorporated was normal. There was no
significant abnormality of iron incorpor-
ation into ferritin or soluble iron com-
plexes.
In vitro marrow responses to erythropoietin
The effect of erythropoietin on haem
synthesis after 4 day culture of marrow
samples is shown in Fig. 3. In the absence
of added Epo there was no significant
difference between the patients (39 ,umol/
1012 cells) and normal controls (4.3 ,tmol/
FIG. 2.-59Fe incorporation into liaem in
patients' marrow cultures after 4 days in-
cubation in basal medium or with the
addition of 0 5 ,u/ml erythropoietin. Shaded
area represents normal range.
was obtained. In 4/12 myeloma patients
where it was possible to make this meas-
urement, values below 2 x 109 cells/kg
were found and 3 of these were patients
with Stage III disease. In the myeloma
patients haemoglobin concentration was
significantly correlated with total marrow
erythroblast population (rs = 0-60, P <
0.05).
In normal subjects (Cavill & Ricketts,
1980) there is a significant negative
correlation between marrow iron turnover
and red-cell lifespan, and this is true for
the present normal group (rs = -0 73,
P<0.001) and for patients with myelo-
matosis (rs=-0-88, P<0.001) but, as
can be seen from Fig. 2, the marrow iron
turnover in myeloma patients is lower
than normal, for the corresponding red-
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FIG. 3. The relationship between marrow
iron turnover and mean red-cell lifespan in
normal subjects 0 and patients with mye-
lomatosis *.
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1012 cells ) (U= 82, P<0 1), though there
was greater variation between patients
than between controls. With the addition
of 0-25 u/ml Epo, the mean 59Fe incropor-
ation in haem was 10.4 tkmol/1012 cells
in the patients compared to 13 1 pkmol/
1012 cells in the control group (U= 53,
P < 0 02) and again haem synthesis was
more variable in the patients than in
the controls, being above abnormal in 2 and
subnormal in 9. The mean percentage
increase in the incorporation of 59Fe in
haem on stimulation with Epo was 1660/
in the patients and 2260O( in normal
.subjects (U=69, P<0l1). There did not
appear to be any relation between the
marrow response to Epo and haemo-
globin concentration, blood urea, seruim
paraprotein concentration, total plasma
cell numbers, marrow iron turnover or
total marrow ervthroblast niumbers.
I)ISCUSSION
Anaemia is a common feature of
tnyelomatosis, being found in 90°O of
patients seen in Edinburgh before 1959
(Innes & Newall, 1961) and 62°, of a
series seen in the Mayo Clinic up to 1971
(Kyle, 1975). 237 out of 485 patients
entering the third MIRC myelomatosis
trial had an initial haemoglobin con-
centration of 1]0 g/dl or less (MRC Working
Party, 1980b). The anaemia has usually
been described as normochromic or normo-
cytic (Innes & Newall, 1961; Kyle, 1975)
and may be the result of haemodilution
due to an expanded plasma volume
(Bjorneboe & Jensen, 1969: Alexanian,
1977) though this is by no means univer-
sally agreed (Cline & Berlin, 1962; Hansen
& Drivsholm, 1 978). It has been suggested
that the haematological changes in myelo-
matosis result from displacement of nor-
mnal marrow by an abnormal growth of
plasma cells (Innes & Newall, 1961;
Kyle, 1975). In addition, megaloblastic
erythropoiesis due to both folate and B12
deficiency has been found in a high pro-
portion of cases (Hoffbrand et al., 1967)
andl about a (uarter of patients have
been estimated1 to be iron deficient
(Hansen, 1978: Birgens et al., 1979).
Sideroblastic changes have been des-
cribed in a fewv patients wvith myelomatosis
(McGibbon & Mollin, 1965: Dacie &
Mollin, 1966) and this feature may pre-
cede the occurrence of myelomatosis in
some cases (Catovsky et al., 1971). In
some patients on long-term chemotherapy
for myelomatosis, sideroblastic anaemia
may precede the onset of actute leukaemia
(Khaleeli et al., 1973). Cline & Berlin
(1962) postulated an erythroid hypoplasia
in myelomatosis which was not related
to the degree of marrow infiltration.
However, their evidence, based largely
on the plasmna iron turnover, was obtained
fiom the investigation of treate(d patients.
Hansen et al. (1 977) found depressed
erythropoietic activity in anaemic patients
with myelomatosis andl assumed that this
was due to renal failure, as venous haema-
tocrit was correlated with glomerular
filtration rate. About a quarter of the
patients sttudied by Cline & Berlin (1962),
Hansen (1978) and Birgens et al. (1979)
had no stainable marrow iron, but Hansen
felt that the normal transferrin saturation
and sideroblast counit in his patients
probably indicated an adequate supply
of iron to the erythroid marrow.
Only 3 of our patients had a low trans-
ferrin saturation, but all of them had
stainable iron in their marrow and serum
ferritin concentrations within or above
the normal range, indicating that iroin
deficiency is not an important factor in
the pathogenesis of their anaemia. We
were not able to confirm the findings by
Hoffbrand et al., (I1967) that folate de-
ficiency andc megaloblastic erythropoiesis
were commoni in patients with myelo-
matosis, but more than half of their cases
had already received chemotherapy or
radiotherapy, and many of them had
light-chain myeloma. In our patients
the negative correlation between serum
folate and paraprotein concentration
suggests a relationship with the disease
process, though only one patient had a
pathologically low serum folate level.
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Anaemia in myeloma patients with
normal renal function suggests that extra-
renal factors may be an important factor
in its aetiology. None of our patients had
subnormal serum lexvels of Epo, and in
patients with normal renal function,
increased concentrations appropriate to
the reduced haemoglobin level were fouind
(Fig. 1). These findings differ from those
of Hansen et al. (1977), who found that
most of their patients had no detectable
circulating Epo. This may have been due
to the lowr sensitivity of their Epo assay,
based on post-hypoxic protein-starved
mice. The mean blood volume of otur
myeloma patientis was 68 6 ml/kg, com-
pared to 63 0 ml/kg in normal subjects,
and although this difference is statistically
significant, its physiological significance
may not be great. However, the negative
correlation between haemoglobin con-
centration and blood v-olume in the patient
indicates that haemodilution is probably
a factior in the pathogenesis of their
anaemia. The correlation between para-
protein concentration and blood volume
suggests that plasma volume expansion
is directly related to the protein abnorm-
ality. There is Ino relationship between
blood volume and paraprotein type in
our patients. The present findings are
in agreement with those of Alexanian
(1977) and Bjorneboe & Jensen (1969)
However, Cline & Berlin (1962) and
Hansen & Drivsholm (1978) found normal
blood volumes in their patients. There
were not only differences in methodology
which might account for the disagree-
ment, buit most, of the patients studied
by Cline and Berlin had already been
given extensive treatment and are thus
not comparable to the present untreated
group. The negativ-e correlation between
serum paraprotein concentration an(d
haemoglobin concentration might be due
partly to the effect of haemodilution, or
might simply reflect an association be-
tween anaemia and the primary disease
process.
Durie & Salmon (1975) proposed a
clinical staging scheme based on correla-
tionis between tumour mass and certain
presenting clinical features. The total
tumouir cell cell number was derived
from measurements of immunoglobulin
synthesis rates by myeloma cells in vitro
and synthetic rate of myeloma protein
measured in vivo. There is some suggestion
from our data that, marrow iron turnover
and erythroblast, numbers may be related
to clinical staging. The total plasma-cell
population estimated byv our method is
somewhat lower than the figures ex-
pectedl from the studies of Durie & Salmon
(1 975) at eachl stage of the disease, though
there is an increase with advancing stages
and there is an overlap with their figures
for Stage 11 patients. The discrepancy is
probably accouinted for by the necessary
assumption in our calculations that the
erythroblast: plasma-cell ratio is constant
throughout the diseased tissues. Plasma-
cytomas would not be accounted for by
our metho(d and the caleculations depencd
-ery much on the plasma-cell content of
the sample aspirated, which may not, of
course, represent the marrow as a whole.
Our myeloma patients showed a de-
crease(l rate of marrow iron turnover,
while red-cell lifespan and ineffective
erythropoiesis remained normal. This
points to a significant impairment of
the erythroid proliferative response to
anaemia. The erythroblasts produced ap-
pear to behave normally. Although ery-
throblast iron uptake was increased in a
few cases, haem synthesis was normal an(d
no abnormal sideroblasts were seen. The
factors controlling erythroid iron uptake
are not understood. The only previous
observations ofincreased uptake have been
in patients with iron deficiency or secon-
dary sideroblastic change (unpublishedl
observations) neither of which are present,
in the cases studied here.
The Epo response of the late erythroid
precursors in marrow cultures was simila,r
in normal and myeloma groups as a
whole, but the patients showed far more
variability than the control subjects,
and in many cases the total iron incorpo-
rated into haem after Epo stimulation was
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subnormal. It is difficult to judge from
the present data whether decreased res-
ponse to Epo may sometimes be important
The reduction in total erythropoiesis
measured by ferrokinetics, together with
normal erythoblast iron uptake, suggests
a reduced input from a precursor compart-
ment, presumably due to a failure of
maturation, though whether this is mani-
fested at BFU-E or CFU-E level is not
obvious. Except in patients with renal
failure, the level of circulating Epo does
not appear to be a limiting factor. In
individual cases a superimposed folate
deficiency may be important, and there
appears to be a haemodilution factor re-
lated to the concentration of circulating
paraprotein. The impression of a con-
tracted erythroid marrow compartment
in myeloma patients is similar to that
found in patients with Hodgkin's disease
(Al Ismail et al., 1979) but in neither case
is there any direct indication of the
precise mechanism.
Dr W. C. Ting is a Leukaemia Research Fund
Fellow.
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